Update on US NDA timelines for NVA237 and QVA149

Update on US NDA timelines for NVA237 and QVA149
25 October 2011

Vectura, Chippenham - 25 October 2011: Vectura Group plc (LSE: VEC) (Vectura), the developer of inhaled pharmaceuticals, notes that Novartis has provided an update on NVA237 and QVA149 in its Q3 results today.

In the US, NVA237 will require additional clinical data to support submission and will consequently be delayed. The changes to the US NVA237 program will similarly impact approval timing for QVA149 in the US, where additional clinical studies will be required. The QVA149 submission remains on track for 2012 in EU and rest of world.

NVA237 (glycopyrronium bromide) has been submitted for approval in the EU under the brand name Seebri Breezhaler, as a once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD). Results from the Phase III GLOW3 study presented at the European Respiratory Society Congress in September, showed that NVA237 50 mcg once-daily produced a 21% improvement in exercise endurance compared to placebo in moderate-to-severe COPD patients. NVA237 was well tolerated, with a similar incidence of adverse events for patients treated with NVA237 and with placebo.

- Ends -

Enquiries

Vectura Group plc

+44 (0)1249 667700

Chris Blackwell, Chief Executive

Anne Hyland, Chief Financial Officer

Julia Wilson, Director of Investor Relations

Financial Dynamics

+44 (0)20 7831 3113

Ben Atwell

Susan Quigley

 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.